The disintegrin-metalloproteinases ADAM 10, 12 and 17 are upregulated in invading peripheral tumor cells of basal cell carcinomas

Journal of Cutaneous Pathology

Volumn 36, Issue 4, 2009, Pages 395-401

  Oh, Shin Taek ^a,b   Schramme, A ^c   Stark, A ^a   Tilgen, W ^a   Gutwein, P ^c   Reichrath, J ^a,d  

^a SAARLAND UNIVERSITY   (Germany)

^b Daejeon St Mary's Hospital   (South Korea)

^c UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^d Leitender Oberarzt und Ständiger Vertreter des Klinikdirektors   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADAM PROTEIN; PROTEIN ADAM 10; PROTEIN ADAM 12; PROTEIN ADAM 17; UNCLASSIFIED DRUG;

ARTICLE; BASAL CELL CARCINOMA; CANCER GROWTH; CANCER INVASION; CANCER PATIENT; CLINICAL ARTICLE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; PATHOGENESIS; PROTEIN EXPRESSION; TUMOR CELL; UPREGULATION;

ADAM PROTEINS; AMYLOID PRECURSOR PROTEIN SECRETASES; CARCINOMA, BASAL CELL; HUMANS; IMMUNOHISTOCHEMISTRY; MEMBRANE PROTEINS; SKIN NEOPLASMS; UP-REGULATION;

EID: 61449141178     PISSN: 03036987     EISSN: 16000560     Source Type: Journal    
DOI: 10.1111/j.1600-0560.2008.01082.x     Document Type: Article

References (57)

1. Bath-Hextall F, Leonardi-Bee J, Smith C, Meal A, Hubbard R. Trends in incidence of skin basal cell carcinoma. Additional evidence from a UK primary care database study. Int J Cancer 2007 121 : 2105.
2. Brodland DG. Diagnosis of nonmelanoma skin cancer. Clin Dermatol 1995 13 : 551.
3. Leppälä J, Kaarniranta K, Uusitalo H, Kontkanen M. Imiquimod in the treatment of eyelid basal cell carcinoma. Acta Ophthalmol Scand 2007 85 : 566.
4. Schiessl C, Wolber C, Tauber M, Offner F, Strohal R. Treatment of all basal cell carcinoma variants including large and high-risk lesions with 5% imiquimod cream: histological and clinical changes, outcome, and follow-up. J Drugs Dermatol 2007 6 : 507.
5. Peris K, Campione E, Micantonio T, et al. Imiquimod treatment of superficial and nodular basal cell carcinoma: 12-week open-label trial. Dermatol Surg 2005 31 : 318.
6. Vun Y, Siller G. Use of 5% imiquimod cream in the treatment of facial basal cell carcinoma: a 3-year retrospective follow-up study. Australas J Dermatol 2006 47 : 169.
7. Merchant NB, Voskresensky I, Rogers CM, et al. TACE/ADAM-17: a component of the epidermal growth factor receptor axis and a promising therapeutic target in colorectal cancer. Clin Cancer Res 2008 14 : 1182.
8. Eichenauer DA, Simhadri VL, von Strandmann EP, et al. ADAM10 inhibition of human CD30 shedding increases specificity of targeted immunotherapy in vitro. Cancer Res 2007 67 : 332.
9. Liu X, Fridman JS, Wang Q, et al. Selective inhibition of ADAM metalloproteases blocks HER-2 extracellular domain (ECD) cleavage and potentiates the anti-tumor effects of trastuzumab. Cancer Biol Ther 2006 5 : 648.
10. Lendeckel U, Kohl J, Arndt M, Carl-McGrath S, Donat H, Rocken C. Increased expression of ADAM family members in human breast cancer and breast cancer cell lines. J Cancer Res Clin Oncol 2005 131 : 41.
11. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002 2 : 161.
12. Wolfsberg TG, Primakoff P, Myles DG, White JM. ADAM, a novel family of membrane proteins containing a disintegrin and metalloprotease domain: multipotential functions in cell-cell and cell-matrix interactions. J Cell Biol 1995 131 : 275.
13. Schlondorff J, Blobel CP. Metalloprotease-disintegrins: modular proteins capable of promoting cell-cell interactions and triggering signals by protein-ectodomain shedding. J Cell Sci 1999 112 : 3603.
14. Ko SY, Lin SC, Wong YK, Liu CJ, Chang KW, Liu TY. Increase of disintergin metalloprotease 10 (ADAM10) expression in oral squamous cell carcinoma. Cancer Lett 2007 245 : 33.
15. Carl-McGrath S, Lendeckel U, Ebert M, Roessner A, Rocken C. The disintegrin-metalloproteinases ADAM9, ADAM12, and ADAM15 are upregulated in gastric cancer. Int J Oncol 2005 26 : 17.
16. Tanaka Y, Miyamoto S, Suzuki SO, et al. Clinical significance of heparin-binding epidermal growth factor-like growth factor and a disintegrin and metalloprotease 17 expression in human ovarian cancer. Clin Cancer Res 2005 11 : 4783.
17. Blanchot-Jossic F, Jarry A, Masson D, et al. Up-regulated expression of ADAM17 in human colon carcinoma: co-expression with EGFR in neoplastic and endothelial cells. J Pathol 2005 207 : 156.
18. Gutwein P, Oleszewski M, Mechtersheimer S, Agmon-Levin N, Krauss K, Altevogt P. Role of Src kinases in the ADAM-mediated release of L1 adhesion molecule from human tumor cells. J Biol Chem 2000 275 : 15490.
19. Mechtersheimer S, Gutwein P, Agmon-Levin N, et al. Ectodomain shedding of L1 adhesion molecule promotes cell migration by autocrine binding to integrins. J Cell Biol 2001 155 : 661.
20. Asakura M, Kitakaze M, Takashima S, et al. Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy. Nat Med 2002 8 : 35.
21. Mochizuki S, Okada Y. ADAMs in cancer cell proliferation and progression. Cancer Sci 2007 98 : 621.
22. Sahin U, Weskamp G, Kelly K, et al. Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands. J Cell Biol 2004 164 : 769.
23. Sunnarborg SW, Hinkle CL, Stevenson M, et al. Tumor necrosis factor-alpha converting enzyme (TACE) regulates epidermal growth factor receptor ligand availability. J Biol Chem 2002 277 : 12838.
24. Yan Y, Shirakabe K, Werb Z. The metalloprotease Kuzbanian (ADAM10) mediates the transactivation of EGF receptor by G protein-coupled receptors. J Cell Biol 2002 158 : 221.
25. Higashiyama S, Nanba D. ADAM-mediated ectodomain shedding of HB-EGF in receptor cross-talk. Biochim Biophys Acta 2005 1751 : 110.
26. Prenzel N, Zwick E, Daub H, et al. EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature 1999 402 : 884.
27. Gschwind A, Hart S, Fischer OM, Ullrich A. TACE cleavage of proamphiregulin regulates GPCR-induced proliferation and motility of cancer cells. EMBO J 2003 22 : 2411.
28. Peschon JJ, Slack JL, Reddy P, et al. An essential role for ectodomain shedding in mammalian development. Science 1998 282 : 1281.
29. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001 2 : 127.
30. Bigelow RL, Jen EY, Delehedde M, Chari NS, McDonnell TJ. Sonic hedgehog induces epidermal growth factor dependent matrix infiltration in HaCaT keratinocytes. J Invest Dermatol 2005 124 : 457.
31. Rippey JJ. Why classify basal cell carcinomas? Histopathology 1998 32 : 393.
32. Saldanha G, Fletcher A, Slater DN. Basal cell carcinoma: a dermatopathological and molecular biological update. Br J Dermatol 2003 148 : 195.
33. Crowson AN. Basal cell carcinoma: biology, morphology and clinical implications. Mod Pathol 2006 19 : S127.
34. Cohen PR, Schulze KE, Nelson BR. Basal cell carcinoma with mixed histology: a possible pathogenesis for recurrent skin cancer. Dermatol Surg 2006 32 : 542.
35. Shannan B, Seifert M, Leskov K, et al. Clusterin (CLU) and melanoma growth: CLU is expressed in malignant melanoma and 1,25-dihydroxyvitamin D3 modulates expression of CLU in melanoma cell lines in vitro. Anticancer Res 2006 26 : 2707.
36. Reichrath J, Kamradt J, Zhu XH, Kong XF, Tilgen W, Holick MF. Analysis of 1,25-dihydroxyvitamin D(3) receptors (VDR) in basal cell carcinomas. Am J Pathol 1999 155 : 583.
37. Dahmane N, Lee J, Robins P, Heller P, Ruiz I, Altaba A. Activation of the transcription factor Gli1 and the Sonic hedgehog signalling pathway in skin tumours. Nature 1997 389 : 876.
38. Saldanha G, Ghura V, Potter L, Fletcher A. Nuclear beta-catenin in basal cell carcinoma correlates with increased proliferation. Br J Dermatol 2004 151 : 157.
39. Reiss K, Maretzky T, Ludwig A, et al. ADAM10 cleavage of N-cadherin and regulation of cell-cell adhesion and beta-catenin nuclear signalling. EMBO J 2005 24 : 742.
40. Fu S, Bottoli I, Goller M, Vogt PK. Heparin-binding epidermal growth factor-like growth factor, a v-Jun target gene, induces oncogenic transformation. Proc Natl Acad Sci U S A 1999 96 : 5716.
41. Downing MT, Brigstock DR, Luquette MH, et al. Immunohistochemical localization of heparin-binding epidermal growth factor-like growth factor in normal skin and skin cancers. Histochem J 1997 29 : 735.
42. Kikuchi A, Sakuraoka K, Shimizu H, Nishikawa T. Immunohistochemical evaluation of epidermis overlying basal cell carcinomas. Br J Dermatol 1993 128 : 644.
43. McCarty MF, Bielenberg DR, Nilsson MB, et al. Epidermal hyperplasia overlying human melanoma correlates with tumour depth and angiogenesis. Melanoma Res 2003 13 : 379.
44. Murai T, Miyauchi T, Yanagida T, Sako Y. Epidermal growth factor-regulated activation of Rac GTPase enhances CD44 cleavage by metalloproteinase disintegrin ADAM10. Biochem J 2006 395 : 65.
45. Murai T, Miyazaki Y, Nishinakamura H, et al. Engagement of CD44 promotes Rac activation and CD44 cleavage during tumor cell migration. J Biol Chem 2004 279 : 4541.
46. Gutwein P, Stoeck A, Riedle S, et al. Cleavage of L1 in exosomes and apoptotic membrane vesicles released from ovarian carcinoma cells. Clin Cancer Res 2005 11 : 2492.
47. Stoeck A, Keller S, Riedle S, et al. A role for exosomes in the constitutive and stimulus-induced ectodomain cleavage of L1 and CD44. Biochem J 2006 393 : 609.
48. Karvinen S, Kosma VM, Tammi MI, Tammi R. Hyaluronan. CD44 and versican in epidermal keratinocyte tumours. Br J Dermatol 2003 148 : 86.
49. Millichip MI, Dallas DJ, Wu E, Dale S, McKie N. The metallo-disintegrin ADAM10 (MADM) from bovine kidney has type IV collagenase activity in vitro. Biochem Biophys Res Commun 1998 245 : 594.
50. Roy R, Wewer UM, Zurakowski D, Pories SE, Moses MA. ADAM 12 cleaves extracellular matrix proteins and correlates with cancer status and stage. J Biol Chem 2004 279 : 51323.
51. Franzke CW, Tasanen K, Schäcke H, et al. Transmembrane collagen XVII, an epithelial adhesion protein, is shed from the cell surface by ADAMs. EMBO J 2002 21 : 5026.
52. Parikka M, Kainulainen T, Tasanen K, Bruckner-Tuderman L, Salo T. Altered expression of collagen XVII in ameloblastomas and basal cell carcinomas. J Oral Pathol 2001 30 : 589.
53. Fairley JA, Heintz PW, Neuburg M, Diaz LA, Giudice GJ. Expression pattern of the bullous pemphigoid-180 antigen in normal and neoplastic epithelia. Br J Dermatol 1995 133 : 385.
54. Baum HP, Meurer I, Unteregger G. Ki-67 antigen expression and growth pattern of basal cell carcinomas. Arch Dermatol Res 1993 285 : 291.
55. Kawaguchi N, Sundberg C, Kveiborg M, et al. ADAM12 induces actin cytoskeleton and extracellular matrix reorganization during early adipocyte differentiation by regulating beta1 integrin function. J Cell Sci 2003 116 : 3893.
56. Cao Y, Kang Q, Zolkiewska A. Metalloprotease-disintegrin ADAM 12 interacts with alpha-actinin-1. Biochem J 2001 357 : 353.
57. Galliano MF, Huet C, Frygelius J, Polgren A, Wewer UM, Engvall E. Binding of ADAM12, a marker of skeletal muscle regeneration, to the muscle-specific actin-binding protein, alpha -actinin-2, is required for myoblast fusion. J Biol Chem 2000 275 : 13933.